Skip to main content

New story in Health from Time: A First-of-its-Kind Library of Potential Coronavirus Drugs, Built at Columbia University, Funded by China’s Richest Person



If our experience with coronaviruses in the past few decades has taught us anything, it’s that outbreaks are inevitable, no matter what we do. You don’t have to look further than the fact that COVID-19 is the third coronavirus epidemic to affect human populations in 20 years, after severe acute respiratory syndromes (SARS) in 2003 and Middle East respiratory syndrome (MERS) in 2012. Coronaviruses make their homes in a variety of animal hosts, from bats to cats, dogs to camels, and it’s just a matter of time before another one makes the jump into people.

Another thing we know for sure is that we can’t rely on patchwork responses each time an outbreak occurs. Every time a new coronavirus emerges, researchers focus their attention on learning everything they can about the culprit, and biotech companies dip a careful toe into the investigational waters of developing a new treatment, but ultimately, when the cases subside, so does the interest and so does the research.

Dr. David Ho, CEO of the Aaron Diamond AIDS Research Center and professor of medicine at Columbia University, wants to put an end to that trend. Ho is a leader in the HIV field, having done groundbreaking research on how the virus works in the body, and pioneering the idea of combating infection early and with the strongest possible arsenal of combined anti-virals. Now, he’s turning to coronaviruses, hoping his HIV expertise will help him figure out how best to treat and contain novel coronaviruses. With a $2.1 million starting grant from Chinese technology mogul Jack Ma, Ho will oversee four research teams at Columbia whose goal is to find an effective treatment against COVID-19 and other coronaviruses.

“We put together a proposal in record time—probably no more than 72 hours,” says Ho. “We predict in the coming decade there will be more [outbreaks]. And we need to find permanent solutions. We should not repeat the mistake we made after SARS and after MERS, that once the epidemic wanes, the interest and the political will and the funding also wanes. If we had followed through with the work that had begun with SARS, we would be so much better off today.”

To ensure that the next response to a coronavirus outbreak is better than this one, Ho and his team are building a first-of-its-kind library of potential coronavirus drug candidates. Coronavirus, like HIV, is a retrovirus, meaning its primary genetic material is made up of RNA, which the virus then translates into DNA when it infects a host cell. So Ho is stacking his shelves with polymerase and protease inhibitors, and other drugs that have been developed to fight HIV and other viruses like viral hepatitis. Ho says there are about 4,700 of these drugs, if you include their analogues (drugs that are structurally similar but may be made using slightly different formulas and might have varying side effect profiles). Because viruses seem to share some basic processes to replicate, that means there’s a strong chance of finding something that might be effective against not just SARS-CoV-2 but other coronaviruses that might pop up in coming years.

Ho is also studying samples from people infected with COVID-19 to find antibodies that might be attacking the virus—applying a strategy his team has been using to find new approaches to treating HIV.

Other researchers are tracking strains of coronavirus currently living in animals like bats, so together with the library of potential drug candidates, Ho says it might be possible to better combat the next coronavirus infection. “We have a goal to have [some] lead candidates [to treat COVID-19] in one year’s time. So we really have to get going,” says Ho. “But if we had done something like this after SARS and MERS, we would be further along already.”

Labels:

Popular posts from this blog

New story in Health from Time: Here’s How Quickly Coronavirus Is Spreading in Your State

The novel coronavirus pandemic is a global crisis, a national emergency and a local nightmare. But while a great deal of the focus in the U.S. has been on the federal government’s response, widely criticized as slow and halting , the picture on the ground remains very different in different parts of the country. A TIME analysis of the per capita spread of the epidemic in all 50 states and Washington, D.C. found considerable range in the rate of contagion, and, in some parts of the country, a significant disparity compared to the national figure. The U.S., unlike nations such as South Korea and now Italy , has yet to show signs of bringing the runaway spread of the virus under control. However, while no single state is yet showing strong signs of bending the curve , some are faring much worse than others. The following graphic plots the rise in the total confirmed cases of COVID-19 per 100,000 residents in each state, plotted by the day that each state reported its first case.
Read more

New story in Health from Time: We Need to Take Care of the Growing Number of Long-term COVID-19 Patients

On July 7, 2020, the Boston Red Sox pitcher Eduardo Rodriguez tested positive for the new coronavirus. He was scheduled to start Opening Day for the Sox, but the virus had other plans— damaging Rodriguez’s heart and causing a condition called myocarditis (inflammation of the heart muscle). Now the previously fit 27-year old ace left-hander must sit out the 2020 season to recover. Rodriguez is not alone in having heart damage from SARS-CoV-2, the virus that causes COVID-19. In a new study done in Germany, researchers studied the hearts of 100 patients who had recently recovered from COVID-19. The findings were alarming: 78 patients had heart abnormalities, as shown by a special kind of imaging test that shows the heart’s structure (a cardiac MRI), and 60 had myocarditis. These patients were mostly young and previously healthy . Several had just returned from ski trips. While other studies have shown a lower rate of heart problems—for example, a study of 416 patients hosp
Read more

New story in Health from Time: U.S. Inmates ‘Mistakenly’ Received COVID-19 Stimulus Checks. Now, the IRS Wants That Money Back

(BOISE, Idaho) — Hundreds of thousands of dollars in coronavirus relief payments have been sent to people incarcerated across the United States, and now the IRS is asking state officials to help claw back the cash that the federal tax agency says was mistakenly sent. The legislation authorizing the payments during the pandemic doesn’t specifically exclude jail or prison inmates, and the IRS has refused to say exactly what legal authority it has to retrieve the money. On its website, it points to the unrelated Social Security Act, which bars incarcerated people from receiving some types of old-age and survivor insurance benefit payments. “I can’t give you the legal basis. All I can tell you is this is the language the Treasury and ourselves have been using,” IRS spokesman Eric Smith said. “It’s just the same list as in the Social Security Act.” Read more: ‘A Double Whammy.’ Those Who Most Need The $1,200 Stimulus Checks May Wait the Longest To Get Them Tax attorney Kell
Read more